Immunoaffinity capture of Extracellular Vesicles

ELISA Immunoplates and Latex or Magnetic Immunobeads for EV capture

Addressing the EV heterogenity is becoming an important issue, in particular, for the different roles that Extracellular Vesicles have in pathological processes such as cancer, infection or neurodegenerative diseases.

HBM-LS provides pre-coated ELISA Immunoplates and Latex or Magnetic Immunobeads for the capture and enrichment of total or specific EV-subpopulations.

Immunobeads for EV capture.
Total EVs (code: HBM-BOLF, HBM-BOLC).
Tumor-Derived EVs (code: HBM-BTLF).

ELISA Immunoplates for EV capture.
Total EVs (code: HBM-POF, HBM-POC).
Tumor-Derived EVs (code: HBM-PTF).

Capture and enrichment of specific EV subpopulations



Characteristics

- Covalentely coated with antibodies
- Suitable for RNA isolation
- Customizable

Applications

- Enrichment of specific EV subpopulations
- Multiple profiling of EV markers
- Total EV capture from human biofluids or cell media

Advantages

- Suitable for EV capture from raw material (whole plasma)
- Ready to use
- Small sample amount required

Address the heterogenity of EVs

Applications of Immunoaffinity EV capture tools

Phenotyping without Extracellular Vesicle pre-purification steps

ELISA Immunoplates can be used for quantitative and qualitative analysis of EV-associated proteins. The plate is able to capture EVs from raw biologic material (plasma, serum, cell medium, etc.). No significant cross-reactivity is observed with soluble antigens.



EV-associated biomarker profiling of plasma from CRC patient. EVs captured by HBM-POF-# plate.

Enrichment of EV subpopulation by ELISA Immunoplates

Immunoplates for Tumor-derived EV enrichment (TM9SF4 coated) are able to distinguish cancer patients (black arrows) from healthy controls.



HBM-PTF (TM9SF4 coated)



HBM-POS (CD9 coated)

Enrichment of Tumor-derived EVs by Latex Immunobeads for cancer marker studies

Latex or Magnetic Immunobeads can be used for capturing EVs from raw biofluids, followed by RNA isolation. The enrichment of miRNA cancer associated (miR16 and miR21) is highly detectable when Immunobeads for capture of Tumor-derived EVs (HBM-BTF; TM9SF4 coated) are used.



Enrichment of miR21 and miR16 in cancer when TM9SF4 coated beads are used



Comparison of detection by WB of total and TM9SF4 positive EVs

HansaBioMed Life Sciences
exosomics

HansaBioMed Life Sciences LTD
Akadeemia Tee 15A, 12618 Tallinn (EE)
Phone: +372 6561996
email: info@hansabiomed.eu
www.hansabiomed.eu

Investors
Lonza
BIOBALT HOLDING
BioFund
Finbiotech srl
BLACK SWAN TRADE Ltd